Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes

David Marrero, John Crean, Bei Zhang, Terrie Kellmeyer, Maurice Gloster, Kathrin Herrmann, Richard Rubin, Naomi Fineberg, Orville Kolterman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

OBJECTIVE - To assess the effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes treated with intensive insulin regimens. RESEARCH DESIGN AND METHODS - Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a double-blind, noninferiority pramlintide dose titration trial. End points included patient reported outcomes, their relationship to insulin treatment regimen, A1C, weight, and insulin use. RESULTS - Pramlintide-treated patients reported greater treatment satisfaction in most questionnaire responses. Treatment satisfaction was similar for pramlintide-treated patients regardless of intensive insulin regimens (MDI versus CSII). Mean A1C was reduced to a similar degree in both pramlintide- (-0.39 ± 0.07%) and placebo-treated (-0.45 ± 0.07%) patients. However, pramlintide treatment was associated with reductions in mean body weight (-1.50 ± 0.33 kg; P < 0.0001) and mealtime insulin use (-19.05 ± 5.17%; P < 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 ± 0.25 kg) and a smaller reduction in mealtime insulin use (-2.20 ± 3.33%). CONCLUSIONS - Despite similar reductions in A1C, pramlintide treatment resulted in greater treatment satisfaction compared with placebo treatment. This was independent of insulin delivery method.

Original languageEnglish
Pages (from-to)210-216
Number of pages7
JournalDiabetes Care
Volume30
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Patient Satisfaction
Type 1 Diabetes Mellitus
Insulin
Therapeutics
Placebos
Subcutaneous Infusions
pramlintide
Meals
Infusion Pumps
Injections
Weight Gain
Research Design
Body Weight
Weights and Measures

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Marrero, D., Crean, J., Zhang, B., Kellmeyer, T., Gloster, M., Herrmann, K., ... Kolterman, O. (2007). Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care, 30(2), 210-216. https://doi.org/10.2337/dc06-1026

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. / Marrero, David; Crean, John; Zhang, Bei; Kellmeyer, Terrie; Gloster, Maurice; Herrmann, Kathrin; Rubin, Richard; Fineberg, Naomi; Kolterman, Orville.

In: Diabetes Care, Vol. 30, No. 2, 02.2007, p. 210-216.

Research output: Contribution to journalArticle

Marrero, D, Crean, J, Zhang, B, Kellmeyer, T, Gloster, M, Herrmann, K, Rubin, R, Fineberg, N & Kolterman, O 2007, 'Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes', Diabetes Care, vol. 30, no. 2, pp. 210-216. https://doi.org/10.2337/dc06-1026
Marrero, David ; Crean, John ; Zhang, Bei ; Kellmeyer, Terrie ; Gloster, Maurice ; Herrmann, Kathrin ; Rubin, Richard ; Fineberg, Naomi ; Kolterman, Orville. / Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. In: Diabetes Care. 2007 ; Vol. 30, No. 2. pp. 210-216.
@article{4ddecd1d1e48488994827b0b5e10452b,
title = "Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes",
abstract = "OBJECTIVE - To assess the effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes treated with intensive insulin regimens. RESEARCH DESIGN AND METHODS - Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a double-blind, noninferiority pramlintide dose titration trial. End points included patient reported outcomes, their relationship to insulin treatment regimen, A1C, weight, and insulin use. RESULTS - Pramlintide-treated patients reported greater treatment satisfaction in most questionnaire responses. Treatment satisfaction was similar for pramlintide-treated patients regardless of intensive insulin regimens (MDI versus CSII). Mean A1C was reduced to a similar degree in both pramlintide- (-0.39 ± 0.07{\%}) and placebo-treated (-0.45 ± 0.07{\%}) patients. However, pramlintide treatment was associated with reductions in mean body weight (-1.50 ± 0.33 kg; P < 0.0001) and mealtime insulin use (-19.05 ± 5.17{\%}; P < 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 ± 0.25 kg) and a smaller reduction in mealtime insulin use (-2.20 ± 3.33{\%}). CONCLUSIONS - Despite similar reductions in A1C, pramlintide treatment resulted in greater treatment satisfaction compared with placebo treatment. This was independent of insulin delivery method.",
author = "David Marrero and John Crean and Bei Zhang and Terrie Kellmeyer and Maurice Gloster and Kathrin Herrmann and Richard Rubin and Naomi Fineberg and Orville Kolterman",
year = "2007",
month = "2",
doi = "10.2337/dc06-1026",
language = "English",
volume = "30",
pages = "210--216",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes

AU - Marrero, David

AU - Crean, John

AU - Zhang, Bei

AU - Kellmeyer, Terrie

AU - Gloster, Maurice

AU - Herrmann, Kathrin

AU - Rubin, Richard

AU - Fineberg, Naomi

AU - Kolterman, Orville

PY - 2007/2

Y1 - 2007/2

N2 - OBJECTIVE - To assess the effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes treated with intensive insulin regimens. RESEARCH DESIGN AND METHODS - Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a double-blind, noninferiority pramlintide dose titration trial. End points included patient reported outcomes, their relationship to insulin treatment regimen, A1C, weight, and insulin use. RESULTS - Pramlintide-treated patients reported greater treatment satisfaction in most questionnaire responses. Treatment satisfaction was similar for pramlintide-treated patients regardless of intensive insulin regimens (MDI versus CSII). Mean A1C was reduced to a similar degree in both pramlintide- (-0.39 ± 0.07%) and placebo-treated (-0.45 ± 0.07%) patients. However, pramlintide treatment was associated with reductions in mean body weight (-1.50 ± 0.33 kg; P < 0.0001) and mealtime insulin use (-19.05 ± 5.17%; P < 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 ± 0.25 kg) and a smaller reduction in mealtime insulin use (-2.20 ± 3.33%). CONCLUSIONS - Despite similar reductions in A1C, pramlintide treatment resulted in greater treatment satisfaction compared with placebo treatment. This was independent of insulin delivery method.

AB - OBJECTIVE - To assess the effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes treated with intensive insulin regimens. RESEARCH DESIGN AND METHODS - Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a double-blind, noninferiority pramlintide dose titration trial. End points included patient reported outcomes, their relationship to insulin treatment regimen, A1C, weight, and insulin use. RESULTS - Pramlintide-treated patients reported greater treatment satisfaction in most questionnaire responses. Treatment satisfaction was similar for pramlintide-treated patients regardless of intensive insulin regimens (MDI versus CSII). Mean A1C was reduced to a similar degree in both pramlintide- (-0.39 ± 0.07%) and placebo-treated (-0.45 ± 0.07%) patients. However, pramlintide treatment was associated with reductions in mean body weight (-1.50 ± 0.33 kg; P < 0.0001) and mealtime insulin use (-19.05 ± 5.17%; P < 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 ± 0.25 kg) and a smaller reduction in mealtime insulin use (-2.20 ± 3.33%). CONCLUSIONS - Despite similar reductions in A1C, pramlintide treatment resulted in greater treatment satisfaction compared with placebo treatment. This was independent of insulin delivery method.

UR - http://www.scopus.com/inward/record.url?scp=33846685521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846685521&partnerID=8YFLogxK

U2 - 10.2337/dc06-1026

DO - 10.2337/dc06-1026

M3 - Article

VL - 30

SP - 210

EP - 216

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 2

ER -